Difference in incidence of peripheral neuropathy in the phase III NSCLC trial

48% of patients who received ABRAXANE + carboplatin experienced any Grade peripheral neuropathy vs 64% of patients treated with paclitaxel injection

Grade 3 peripheral neuropathy in the ABRAXANE + carboplatin arm vs paclitaxel + carboplatin

Neuropathy in non-small cell lung cancer

Additional information about peripheral neuropathy in the ABRAXANE arm

  • 1% of patients discontinued ABRAXANE due to peripheral neuropathy
  • No patients in the ABRAXANE + carboplatin arm developed Grade 4 peripheral neuropathy
  • If ? Grade 3 sensory neuropathy develops, treatment should be withheld until resolution to ? Grade 1 for NSCLC followed by a permanent dose reduction for all subsequent courses of ABRAXANE
View dose level modifications

Difference in incidence of peripheral neuropathy in the phase III NSCLC trial

48% of patients who received ABRAXANE + carboplatin experienced any Grade peripheral neuropathy vs 64% of patients treated with paclitaxel injection

Grade 3 peripheral neuropathy in the ABRAXANE + carboplatin arm vs paclitaxel + carboplatin

Neuropathy in non-small cell lung cancer

Additional information about peripheral neuropathy in the ABRAXANE arm

View dose level modifications
  • 1% of patients discontinued ABRAXANE due to peripheral neuropathy
  • No patients in the ABRAXANE + carboplatin arm developed Grade 4 peripheral neuropathy
  • If ? Grade 3 sensory neuropathy develops, treatment should be withheld until resolution to ? Grade 1 for NSCLC followed by a permanent dose reduction for all subsequent courses of ABRAXANE

INDICATION

ABRAXANE is indicated for the first-line treatment of locally advanced or metastatic non–small cell lung cancer, in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy.

INDICATION

ABRAXANE is indicated for the first-line treatment of locally advanced or metastatic non–small cell lung cancer, in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy.